# The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes

> **NCT06000462** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Oman Ministry of Health** · enrollment: 150 (estimated)

## Conditions studied

- Obesity
- Dapagliflozin Adverse Reaction
- Weight Loss
- Effect of Drug

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Metformin 1000 mg (ttd)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06000462
- **Lead sponsor:** Oman Ministry of Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06000462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06000462, "The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06000462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*